文献速递胸部肿瘤

德国国家基因组医学肺癌网络:帕博利珠单抗一线治疗程序性死亡配体1高表达(≥50%)非鳞状非小细胞肺癌的结局与KRAS/TP53突变状态的关系

Outcome of First-Line Treatment With Pembrolizumab According to KRAS/TP53 Mutational Status for Nonsquamous Programmed Death-Ligand 1-High (≥50%) NSCLC in the German National Network Genomic Medicine Lung Cancer.
PubMed 文献 · J Thorac Oncol · 2023-12-13

该回顾性队列分析纳入2017至2020年德国国家基因组医学肺癌网络中696例程序性死亡配体1高表达(≥50%)、非鳞状非小细胞肺癌、东部肿瘤协作组体能状态评分≤1且接受帕博利珠单抗一线姑息治疗的患者,按KRAS/TP53状态分析疗效并与肿瘤微环境及癌症基因组图谱肺腺癌队列基因表达关联。KRAS突变者中TP53共突变提高缓解率、无进展生存和总生存,KRAS野生型者无差异;G12C/TP53共突变者无进展生存和总生存最长。

要点

  • KRAS突变患者中TP53共突变与更高缓解率、更长无进展生存和总生存相关。
  • KRAS野生型患者中TP53状态未见差异。
  • G12C/TP53共突变者无进展生存33.7个月、总生存65.3个月,为最长。

核心结论

  • G12C/TP53共突变识别出免疫检查点抑制剂单药治疗长期生存非常有利的一类患者,由促炎肿瘤微环境中高度活跃的干扰素γ信号介导。

研究设计与样本

  • 回顾性队列分析纳入2017至2020年德国国家基因组医学肺癌网络中696例连续的程序性死亡配体1高表达(≥50%)、非鳞状非小细胞肺癌患者,东部肿瘤协作组体能状态评分≤1,接受帕博利珠单抗一线姑息治疗。
  • 按KRAS/TP53状态分析治疗疗效和结局,并与肿瘤微环境组成及癌症基因组图谱肺腺癌队列基因表达分析关联。

主要发现

  • KRAS突变比例为53%(G12C 25%,非G12C 28%),TP53突变比例为51%。
  • KRAS突变患者中,TP53共突变较野生型提高缓解率:G12C组69.7% vs 46.5%(p=0.004),非G12C组55.4% vs 39.5%(p=0.03)。
  • KRAS突变患者中,TP53共突变较野生型延长无进展生存:G12C组HR=0.59(p=0.009),非G12C组HR=0.7(p=0.047)。
  • KRAS突变患者中,TP53共突变较野生型延长总生存:G12C组HR=0.72(p=0.16),非G12C组HR=0.56(p=0.002);KRAS野生型患者中未观察到差异。
  • 中位随访41个月后,G12C/TP53突变患者无进展生存和总生存最长(分别为33.7个月和65.3个月),与肿瘤微环境中肿瘤浸润淋巴细胞密度高及干扰素γ靶基因上调相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Programmed death-ligand 1 expression currently represents the only validated predictive biomarker for immune checkpoint inhibition in metastatic NSCLC in the clinical routine, but it has limited value in distinguishing responses. Assessment of KRAS and TP53 mutations (mut) as surrogate for an immunosupportive tumor microenvironment (TME) might help to close this gap. METHODS: A total of 696 consecutive patients with programmed death-ligand 1-high (≥50%), nonsquamous NSCLC, having received molecular testing within the German National Network Genomic Medicine Lung Cancer between 2017 and 2020, with Eastern Cooperative Oncology Group performance status less than or equal to 1 and pembrolizumab as first-line palliative treatment, were included into this retrospective cohort analysis. Treatment efficacy and outcome according to KRAS/TP53 status were correlated with TME composition and gene expression analysis of The Cancer Genome Atlas lung adenocarcinoma cohort. RESULTS: Proportion of KRASmut and TP53mut was 53% (G12C 25%, non-G12C 28%) and 51%, respectively. In KRASmut patients, TP53 comutations increased response rates (G12C: 69.7% versus 46.5% [TP53mut versus wild-type (wt)], p = 0.004; non-G12C: 55.4% versus 39.5%, p = 0.03), progression-free survival (G12C: hazard ratio [HR] = 0.59, p = 0.009, non-G12C: HR = 0.7, p = 0.047), and overall survival (G12C: HR = 0.72, p = 0.16, non-G12C: HR = 0.56, p = 0.002), whereas no differences were observed in KRASwt patients. After a median follow-up of 41 months, G12C/TP53mut patients experienced the longest progression-free survival and overall survival (33.7 and 65.3 mo), which correlated with high tumor-infiltrating lymphocyte densities in the TME and up-regulation of interferon gamma target genes. Proinflammatory pathways according to TP53 status (mut versus wt) were less enhanced and not different in non-G12C and KRASwt, respectively. CONCLUSIONS: G12C/TP53 comutations identify a subset of patients with a very favorable long-term survival with immune checkpoint inhibitor monotherapy, mediated by highly active interferon gamma signaling in a proinflammatory TME.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Bischoff P, Reck M, Overbeck T, et al. Outcome of First-Line Treatment With Pembrolizumab According to KRAS/TP53 Mutational Status for Nonsquamous Programmed Death-Ligand 1-High (≥50%) NSCLC in the German National Network Genomic Medicine Lung Cancer. J Thorac Oncol. 2023. PMID: 38096950. doi:10.1016/j.jtho.2023.12.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。